glp-1 and psoriatic arthritis drugs Ozempic, Zepbound, Mounjaro for Psoriasis and Psoriasis Uncovered: GLP-1 & GIP

The PA criteria require BMI 30 or higher (or 27 with a comorbidity such as type 2 diabetes, hypertension, dyslipidemia, OSA, or CVD), documentation of a 6-month structured weight management program, prescriber attestation that lifestyle change alone has failed, and age 18 or older

demonstrated that semaglutide had similar effects in an ovariectomized rat model, increasing -catenin expression and reducing RANKL production, which resulted in a net increase in bone formation

This is still an area of active study, but it's a promising development

Common side effects are gastrointestinal (nausea, diarrhoea, vomiting) and typically occur during initial treatment or dose increases

Our results show that the lipolytic effect of exenatide on WAT is SIRT1 dependent